Completed PHASE2 INTERVENTIONAL 2-arm NCT01064830

Topical Cyclosporine Suspension for the Treatment of Brittle Nails

A Single Center, Investigator-blinded Study of the Efficacy of Topical Cyclosporine 0.05% Ophthalmic Suspension (RESTASIS®) Under Occlusion Versus Vehicle in the Treatment of Brittle Nail Syndrome

Sponsor: Allergan

Conditions Brittle Nail Syndrome

Interventions topical cyclosporine ophthalmic suspension 0.05% vehicle

Updated 8 times since 2017 Last updated: Feb 1, 2017 Started: Feb 28, 2010 Primary completion: Aug 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Brittle Nail Syndrome, this trial is completed. The trial is conducted by Allergan and has accumulated 8 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan
University of North Carolina, Chapel Hill

Data source: University of North Carolina, Chapel Hill

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chapel Hill, United States